ORI
ALXN

Oak Ridge Investments’s Alexion Pharmaceuticals ALXN Stock Holding History

Oak Ridge Investments’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-28,334
Closed -$5.21M – 178
2021
Q2 		$5.21M Sell
28,334
-596
-2% -$102K 0.45% 78
2021
Q1 		$4.42M Buy
28,930
+182
+0.6% +$28.2K 0.41% 91
2020
Q4 		$4.49M Sell
28,748
-13,011
-31% -$1.67M 0.4% 94
2020
Q3 		$4.78M Sell
41,759
-552
-1% -$59.5K 0.37% 95
2020
Q2 		$4.75M Sell
42,311
-177
-0.4% -$18.8K 0.4% 89
2020
Q1 		$3.81M Sell
42,488
-5,097
-11% -$500K 0.39% 90
2019
Q4 		$5.15M Sell
47,585
-7,291
-13% -$780K 0.38% 94
2019
Q3 		$5.38M Sell
54,876
-2,705
-5% -$305K 0.4% 87
2019
Q2 		$7.54M Sell
57,581
-14,319
-20% -$1.85M 0.52% 83
2019
Q1 		$9.72M Buy
71,900
+3,732
+5% +$464K 0.62% 69
2018
Q4 		$6.64M Sell
68,168
-7,669
-10% -$907K 0.48% 78
2018
Q3 		$10.5M Sell
75,837
-4,381
-5% -$550K 0.58% 72
2018
Q2 		$9.96M Sell
80,218
-2,549
-3% -$298K 0.56% 77
2018
Q1 		$9.22M Sell
82,767
-1,487
-2% -$178K 0.51% 79
2017
Q4 		$10.1M Sell
84,254
-14,265
-14% -$1.74M 0.48% 81
2017
Q3 		$13.8M Buy
98,519
+10,338
+12% +$1.4M 0.56% 70
2017
Q2 		$10.7M Buy
88,181
+3,556
+4% +$414K 0.34% 85
2017
Q1 		$10.3M Buy
84,625
+11,943
+16% +$1.54M 0.34% 80
2016
Q4 		$8.89M Buy
72,682
+26,993
+59% +$3.3M 0.29% 78
2016
Q3 		$5.6M Sell
45,689
-1,360
-3% -$175K 0.15% 101
2016
Q2 		$5.49M Sell
47,049
-162
-0.3% -$23K 0.14% 103
2016
Q1 		$6.57M Sell
47,211
-656
-1% -$96.3K 0.17% 100
2015
Q4 		$9.13M Buy
47,867
+445
+0.9% +$77.7K 0.22% 96
2015
Q3 		$7.42M Sell
47,422
-86
-0.2% -$15.7K 0.18% 103
2015
Q2 		$8.59M Sell
47,508
-47
-0.1% -$8.11K 0.18% 104
2015
Q1 		$8.24M Sell
47,555
-552
-1% -$99.9K 0.18% 107
2014
Q4 		$8.9M Sell
48,107
-1,576
-3% -$292K 0.21% 101
2014
Q3 		$8.24M Buy
49,683
+35,550
+252% +$5.84M 0.21% 104
2014
Q2 		$2.21M Buy
14,133
+12,806
+965% +$2.02M 0.05% 129
2014
Q1 		$202K Buy
+1,327
New +$211K 0.01% 139

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Oak Ridge Investments's ALXN Position: Q3 2021 in Review

Oak Ridge Investments sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 28,334 shares — an estimated $5.21M sold.

Oak Ridge Investments first reported a position in ALXN in Q1 2014 and held it in 30 quarters. The position peaked at $13.8M in Q3 2017. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Oak Ridge Investments reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Oak Ridge Investments sold 28,334 Alexion Pharmaceuticals shares in Q3 2021, an estimated $5.21M.
  • Oak Ridge Investments first reported a position in Alexion Pharmaceuticals in Q1 2014 and held it in 30 quarters.
  • Oak Ridge Investments's Alexion Pharmaceuticals position peaked at $13.8M in Q3 2017.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Oak Ridge Investments's 13F filing for Q3 2021, filed 5 Nov 2021.